Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of one systematic review/meta-analysis. ^[1]
• Tapinarof cream (1%) showed superior effectiveness compared to placebo with odds ratio (OR) = 8.3 (5.5, 13.0) at 4 weeks, OR = 8.3 (5.9, 13.0) at 8 weeks, and OR = 7.3 (5.1, 11.0) at 12 weeks, in adult patients with psoriasis. It was also superior to calcipotriol at all measured time points (4, 8, and 12 weeks).
• The incidence of adverse events was higher with 1% tapinarof cream compared to placebo (OR: 3.3 [2.6, 4.3]), although no serious systemic adverse events were reported. It also had a higher incidence of adverse events compared to calcipotriol, but no specific OR values were provided for this comparison.
• The incidence of adverse events was higher for patients using 1% tapinarof cream compared to placebo [OR: 3.3], with no serious systemic adverse events reported.
• The incidence of adverse events was higher for 1% tapinarof cream compared to calcipotriol, though no specific OR values are provided for this comparison.
• There is no population types or subgroups information available in the reviewed documents.